- Fairly valued with a synthesized target of $132.47 compared to a current price of $134.06.
- Dominant but mature HIV franchise faces long-term growth constraints and patent expirations.
- Immense free cash flow easily supports a robust dividend and ongoing strategic oncology investments.
- Near-term multiple expansion requires significant commercial breakthroughs in the oncology pipeline.
Fair value
$132
Margin of safety
-1.2%
Confidence
88/100
Moat
6.5/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.